| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 11/26/2009 | US20090291995 bis-(monoethanolamine) salt of 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; enhanced solubility and bioavailability compared with free acid; agonist of TPO receptor, enhances platelet production; thrombocytopenia |
| 11/26/2009 | US20090291909 Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue |
| 11/26/2009 | US20090291888 Modulators of tnf receptor associated factor (traf), their preparation and use |
| 11/26/2009 | US20090291429 Substances causing differentiation |
| 11/26/2009 | US20090291075 Binding agents and their use in targeting tumor cells |
| 11/26/2009 | US20090291061 Stem cell therapy for blood vessel degeneration |
| 11/26/2009 | DE10317922B4 Verwendung eines Kombinationspräparates aus oralem Kontrazeptivum und Calcium/Vitamin D The use of a combination product of oral contraceptive and calcium / vitamin D |
| 11/26/2009 | CA2725535A1 Modified drugs for use in liposomal nanoparticles |
| 11/26/2009 | CA2724983A1 Composition for preventing cardiovascular event in high-risk patient |
| 11/26/2009 | CA2724594A1 Niacin and nsaid combination therapy |
| 11/26/2009 | CA2724592A1 Agent for maintenance of induced remission |
| 11/26/2009 | CA2724412A1 Maintenance therapy regimen for treating acne |
| 11/25/2009 | EP2123674A1 Treatment of fibrosis by antagonism of IL-13 and/or IL-13 receptor |
| 11/25/2009 | EP2123672A1 Modulation of IL-2- and IL-15- mediated T cell responses |
| 11/25/2009 | EP2123669A1 Copolymers for suppression of autoimmune diseases, and methods of use |
| 11/25/2009 | EP2123665A2 Inhibitors of interleukin-1Beta converting enzyme |
| 11/25/2009 | EP2123303A1 Ameliorating agent for insulin resistance |
| 11/25/2009 | EP2123302A1 Chronic rejection inhibitor |
| 11/25/2009 | EP2123301A1 Therapeutic agent for urinary tract disease |
| 11/25/2009 | EP2123295A1 Therapeutic agent for interstitial pneumonia |
| 11/25/2009 | EP2123293A2 Peptide YY and petide YY agonists for treatment of metabolic disorders |
| 11/25/2009 | EP2123273A1 Therapeutic agent for urinary excretion disorder |
| 11/25/2009 | EP2123252A1 Method for increasing hair growth |
| 11/25/2009 | EP2121001A2 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| 11/25/2009 | EP2120998A2 Modified erythropoietin polypeptides and uses thereof for treatment |
| 11/25/2009 | EP2120919A1 New combination for use in the treatment of inflammatory disorders |
| 11/25/2009 | EP2120912A1 Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor |
| 11/25/2009 | EP2120909A2 Treatments of therapy-resistant diseases comprising drug combinations |
| 11/25/2009 | EP1663398B1 Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
| 11/25/2009 | EP1390041B1 Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| 11/25/2009 | EP1322299B1 Composition for the transdermal delivery of fentanyl |
| 11/25/2009 | EP1242385B1 Cytokine, especially tnf-alpha, inhibitors |
| 11/25/2009 | EP1210108B1 Use of leptin together with an inhibitor of vegf and/or an inhibitor of angiogenesis for the inhibition of endothelial cell proliferation |
| 11/25/2009 | EP1019490B1 Methods for modulating hematopoiesis and vascular growth |
| 11/25/2009 | CN101588843A Assay |
| 11/25/2009 | CN101588813A Method of inducing neutralizing antibodies to human immunodeficiency virus |
| 11/25/2009 | CN101588810A Composition comprising Trachelospermi caulis and Pyrola japonica extracts for the treatment and prevention of inflammatory diseases |
| 11/25/2009 | CN101586142A Research approach for element for forcing knubble microenvironment and application thereof |
| 11/25/2009 | CN101585881A An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 11/25/2009 | CN101584863A Medicament for external use for treating onychomycosis |
| 11/25/2009 | CN101584862A Diagnosing tumorigenicity and determining resistance to anticancer therapy |
| 11/25/2009 | CN101584681A Tablet capsule for treating helicobacter pylori infection |
| 11/25/2009 | CN100562748C Method of predicting spot formation on the skin with the use of spot site-accelerating genes as indication and method of screening inhibitor for spot formation on the skin |
| 11/25/2009 | CN100562339C Remedies for infact chronic arthritis-relating diseases |
| 11/25/2009 | CN100562311C Cisplatin preparation method and its application method |
| 11/24/2009 | US7622556 Modified cytokines for use in cancer therapy |
| 11/24/2009 | US7622530 Biocompatible block copolymer comprising one or more elastomeric blocks and one or more thermoplastic blocks connected by a seed polymer |
| 11/24/2009 | US7622502 Rheumatic diseases, influenza, common cold, pain, dysmenorrhea, headache, toothache, sprains and strains, neuralgia, synovitis,arthritis, osteoarthritis, gout, bursitis, burns, injuries, and inflammation; cardiovascular disorders, anticoagulants; side effect reduction |
| 11/24/2009 | US7622472 Combination of Src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| 11/24/2009 | US7622128 Porphyromonas gingivalis 1435/1449 LPS as an immune modulator |
| 11/24/2009 | US7622121 Heat shock proteins from Mycobacterium leprae and uses thereof |
| 11/24/2009 | US7622115 Treatment with anti-VEGF antibodies |
| 11/24/2009 | CA2493336C Composition for solubilization of paclitaxel and preparation method thereof |
| 11/24/2009 | CA2475712C Nicotinamide derivatives useful as pde4 inhibitors |
| 11/24/2009 | CA2448030C Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester |
| 11/24/2009 | CA2445678C Paroxetine controlled release compositions |
| 11/24/2009 | CA2433197C Gyrase inhibitors and uses thereof |
| 11/24/2009 | CA2431834C Methods and formulations for the treatment of female sexual dysfunction |
| 11/24/2009 | CA2431355C 14.beta., 16,17-methylene steroids as novel androgens |
| 11/24/2009 | CA2423930C Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid |
| 11/24/2009 | CA2423836C Composition for the delivery of fentanyl |
| 11/24/2009 | CA2423384C New cross-linked derivatives of hyaluronic acid |
| 11/24/2009 | CA2413337C Bioadhesive compositions and methods of preparation and use |
| 11/24/2009 | CA2383499C Drug delivery device |
| 11/24/2009 | CA2360039C Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections |
| 11/24/2009 | CA2350638C Biologically active implants coated with a biodegradable polymer |
| 11/24/2009 | CA2265912C Human bad polypeptides, encoding nucleic acids and methods of use |
| 11/24/2009 | CA2201105C Inhibitor of stem cell proliferation and uses thereof |
| 11/19/2009 | WO2009140201A1 Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
| 11/19/2009 | WO2009139921A2 Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| 11/19/2009 | WO2009139766A1 Anticancer combination therapy including triciribine |
| 11/19/2009 | WO2009139506A1 Combination of drugs having different physical properties into single dosage form |
| 11/19/2009 | WO2009139468A1 Coccidiosis control agent and feed containing the same |
| 11/19/2009 | WO2009139459A1 Method for prevention and treatment of metabolic syndrome through the inhibition of psgl-1 |
| 11/19/2009 | WO2009139362A1 Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form |
| 11/19/2009 | WO2009139168A1 Therapeutic agent for pain |
| 11/19/2009 | WO2009139167A1 Nutrient composition capable of adjusting energy amount, water amount and salt equivalent |
| 11/19/2009 | WO2009138843A1 Glycosaminoglycan oral use and compositions |
| 11/19/2009 | WO2009138516A1 Therapy regimen for treating acne related diseases |
| 11/19/2009 | WO2009138509A1 Multiple myeloma treatments |
| 11/19/2009 | WO2009138165A1 Sgc stimulators, sgc activators and combinations thereof for the treatment of hearing impairment |
| 11/19/2009 | WO2009123457A3 Ubiquitin alone or in combination for use in the treatment of sweet itch |
| 11/19/2009 | WO2009065947A3 Pharmaceutical composition containing a zeolite/algae or zeolite/emulsion combination for the treatment of aids |
| 11/19/2009 | WO2009051824A3 Combination analgesic employing opioid and neutral antagonist |
| 11/19/2009 | WO2009015447A3 Polyacetal-carboxylic acids in the treatment of cancer and auto-immune disorders |
| 11/19/2009 | WO2008131940A3 Combination of immunological agent and sensitizing agent for the treatment of cancer |
| 11/19/2009 | WO2008128049A3 Tetrahydrobiopterin compositions and methods of measuring |
| 11/19/2009 | US20090286865 Potentiator of antitumoral agents in the treatment of cancer |
| 11/19/2009 | US20090286858 Assays for modulators of asparaginyl hydroxylase |
| 11/19/2009 | US20090286743 Methods and Compositions for Treating Conditions of the Eye |
| 11/19/2009 | US20090286737 Erbb interface peptidomimetics and methods of use thereof |
| 11/19/2009 | US20090286720 Pharmaceutical composition for the diagnosis, prevention or treatment of a tumoral pathology comprising an agent modulating the polymerization state of actin |
| 11/19/2009 | US20090285908 Method of treating endothelial injury |
| 11/19/2009 | US20090285843 Epitope sequences |
| 11/19/2009 | US20090285822 Prevention and treatment of amyloidogenic disease |
| 11/19/2009 | US20090285817 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 11/19/2009 | US20090285814 CD 40 Binding Molecules and CTL Pepetides for Treating Tumors |
| 11/19/2009 | US20090285809 Prevention and treatment of amyloidogenic diseases |
| 11/19/2009 | US20090285792 Compositions and methods for treatment of neovascular diseases |
| 11/19/2009 | US20090285778 Use of interleukin-19 to treat cervical cancer |